Aardvark Adventures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures

DAVE 203.85

+0.5%

Dec 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ~digs	6/24/2007 12:35:52 AM
	of 7944

[ULUR.OB] ULURU INC » 4.84 -0.1 ( -2.02%) Open » 4.95 Volume » 72576 ULURU, Inc., a pharmaceutical company, engages in the research, development, and commercialization of wound management, plastic surgery, and oral care products worldwide. The company owns three patented drug delivery technologies: OraDisc, Nanoparticle Aggregate, and Residerm. Its products include Aphthasol and Aptheal (Amlexanox 5% Paste) for the treatment of canker sores; Residerm A gel-Zindaclin (Zinc-Clindamycin) for the treatment of acne; and OraDisc for the treatment of oral conditions relies upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth. The company has license agreement with ProStrakan Limited for the manufacture, sale, and marketing of zinc clindamycin; and strategic partnership agreement with BioProgress PLC to co-develop OraDisc B for the treatment of nausea and vomiting utilizing the mucoadhesive disc technology. uluruinc.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next